Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27354286 | 0.84 | ALOX15 (0.37) | KISS1RDPP7MEN1KMT2A | |
| SCHEMBL18233190 | 0.83 | KISS1R (0.38) | KISS1RKDM4EMAPK1HIF1ADPP7 | |
| SCHEMBL14509061 | 0.83 | KISS1R (0.38) | KISS1RKDM4EMAPK1HIF1ADPP7 | |
| SCHEMBL18233928 | 0.81 | BLM (0.46) | KISS1RKDM4EMAPK1HIF1AMEN1 | |
| SCHEMBL15030995 | 0.81 | BLM (0.46) | KISS1RKDM4EMAPK1HIF1AMEN1 | |
| SCHEMBL14769718 | 0.81 | DPP7 (0.49) | KISS1RDPP7 | |
| SCHEMBL13319577 | 0.81 | DPP7 (0.49) | KISS1RDPP7 | |
| SCHEMBL22807623 | 0.80 | CNR1 (0.33) | KISS1RDPP7CNR1 | |
| SCHEMBL25477138 | 0.80 | KDM4E (0.34) | KISS1RKDM4EMAPK1HIF1ADPP7 | |
| SCHEMBL14509190 | 0.80 | KDM4E (0.34) | KISS1RKDM4EMAPK1HIF1ADPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759104-B2 | Cationic lipids | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2014-06-24 | — | — | US | disclosed |
| US-20130065308-A1 | CATIONIC LIPIDS | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2013-03-14 | — | — | US | disclosed |
| WO-2007115182-A2 | LINEAR NATRIURETIC PEPTIDE CONSTRUCTS | PALATIN TECHNOLOGIES, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065308-A1 | CATIONIC LIPIDS | PLIN5, LPCAT3, IPO5 | KISS1R 2809/4885KDM4E 2442/4885MAPK1 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.